DIM
EPZM

Delta Investment Management’s Epizyme, Inc EPZM Stock Holding History

Delta Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-104,576
Closed -$2.57M – 154
2019
Q4 		$2.57M Buy
+104,576
New +$1.55M 0.94% 26

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Delta Investment Management's EPZM Position: Q1 2020 in Review

Delta Investment Management sold out of Epizyme, Inc (EPZM) in Q1 2020, closing a stake of 104,576 shares — an estimated $2.57M sold.

Delta Investment Management first reported a position in EPZM in Q4 2019 and held it in 1 quarter. The position peaked at $2.57M in Q4 2019. 143 funds tracked by Wall St. Rank hold EPZM as of Q1 2020.

  • Delta Investment Management reported no remaining Epizyme, Inc position as of Q1 2020 after selling out during the quarter.
  • Delta Investment Management sold 104,576 Epizyme, Inc shares in Q1 2020, an estimated $2.57M.
  • Delta Investment Management first reported a position in Epizyme, Inc in Q4 2019 and held it in 1 quarter.
  • Delta Investment Management's Epizyme, Inc position peaked at $2.57M in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2020.

Based on Delta Investment Management's 13F filing for Q1 2020, filed 14 May 2020.